Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe

Southern African Journal of HIV Medicine

 
 
Field Value
 
Title Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
 
Creator Mandikiyana Chirimuta, Linda A. Pascoe, Margaret J. Lowe, Sara
 
Subject Virology; Medicine; Clinical Science HIV drug resistance; dolutegravir; integrase strand inhibitor; antiretroviral treatment; HIV
Description We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG.What this study adds: Dolutegravir is the mainstay of HIV treatment programmes and emergence of drug resistance to DTG is of public health relevance.
 
Publisher AOSIS
 
Contributor none
Date 2022-10-26
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Case report
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajhivmed.v23i1.1435
 
Source Southern African Journal of HIV Medicine; Vol 23, No 1 (2022); 3 pages 2078-6751 1608-9693
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajhivmed.org.za/index.php/hivmed/article/view/1435/2900 https://sajhivmed.org.za/index.php/hivmed/article/view/1435/2901 https://sajhivmed.org.za/index.php/hivmed/article/view/1435/2902 https://sajhivmed.org.za/index.php/hivmed/article/view/1435/2903
 
Coverage Southern Africa — People living with HIV
Rights Copyright (c) 2022 Linda A. Mandikiyana Chirimuta, Margaret J. Pascoe, Sara Lowe https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT

International Tel: 021 975 2602

15 Oxford street, Durbanville, Cape Town, 7550 (South Africa)
Copyright © AOSIS (Pty) Ltd. All rights reserved.
No unauthorised duplication allowed